Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Journal of the Neurological Sciences

Volumn 308, Issue 1-2, 2011, Pages 98-102

  Kerbrat, A ^a   Le Page, E ^a   Leray, E ^a,b   Anani, T ^c   Coustans, M ^d   Desormeaux, C ^e   Guiziou, C ^f   Kassiotis, P ^g   Lallement, F ^h   Laplaud, D ⁱ   Diraison, P ^d   Rouhart, F ^j   Sartori, E ^k   Wardi, R ^h   Wiertlewski, S ⁱ   Edan, G ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c Centre Hospitalier de Pontivy   (France)

^d Centre Hospitalier de Quimper   (France)

^e Centre Hospitalier de la Roche sur Yon   (France)

^f Centre Hospitalier de Lannion   (France)

^g Centre Hospitalier de Vannes   (France)

^h Centre Hospitalier de Saint Brieuc   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j BREST UNIVERSITY HOSPITAL   (France)

^k Centre Hospitalier de Lorient   (France)

more..

Author keywords

Drug holiday; Multiple Sclerosis; Natalizumab; Progressive multifocal leucoencephalopathy

Indexed keywords

GADOLINIUM; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; FRANCE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REBOUND; RELAPSE; RETROSPECTIVE STUDY;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 80051670102     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.05.043     Document Type: Article

References (18)

1. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D. Miller A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
2. C. Bozic, L. Christiano, R. Hyde, A. Natarajan, and M. Kooijmans-Coutinho Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis Mult Scler 16 Suppl. 10 2010 S315
3. D.B. Clifford, A. DeLuca, D.M. Simpson, G. Arendt, G. Giovannoni, and A. Nath Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 2010 438 446
4. European Agency for the Evaluation of Medicinal Products Tysabri® summary of product characteristics Available from URL http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/000603/WC500044686. pdf Accessed October 20, 2010
5. H.P. Hartung New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab Lancet Neurol 8 2009 28 31
6. S.L. Hauser, and S.C. Johnston Balancing risk and reward: the question of natalizumab Ann Neurol 66 3 2009 A7 A8
7. P.W. O'Connor, A. Goddman, L. Kappos, F.D. Lublin, D.H. Miller, and C.H. Polman Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis Mult Scler 12 2006 S18
8. B.O. Khatri, S. Man, G. Giovannoni, A.P. Koo, J.C. Lee, and B. Tucky Effect of plasma exchange in accelerating natalizumab clearance and restauring leukocytes function Neurology 75 2009 396 401
9. O. Stüve, C.M. Marra, K.R. Jerome, L. Cook, P.D. Cravens, and S. Cepok Immune surveillance in multiple sclerosis patients treated with natalizumab Ann Neurol 59 2006 May 743 747
10. C. Poser, D. Paty, L. Scheinberg, W. Mc Donald, and F. Davis New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 1983 227 231
11. D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G. Rice for the international natalizumab multiple sclerosis trial group A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 2003 15 23
12. M.M. Vellinga, J.A. Castelijns, F. Barkhof, B.M.J. Uitdehaag, and C.H. Polman Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients Neurology 70 2008 1150 1151
13. T.W. West, and B. Cree Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68 2010 395 399
14. J. Killestein, A. Vennegoor, E.M. Strijbis, A. Seewann, B. van Oosten, and B. Uitdehaag Natalizumab drug holiday in multiple sclerosis: poorly tolerated Ann Neurol 68 2010 392 395
15. A. Miravalle, R. Jensen, and P. Kinkel Immune reconstitution inflammatory symdrome in patients with multiple sclerosis following cessation of natalizumab therapy Arch Neurol October 11 2010 10.1001/archneurol.2010.257 OnlineFirst
16. T. Lenhard, A. Biller, W. Mueller, I. Metz, J. Schönberger, and B. Wildemann Immune reconstitution inflammatory symdrome after withdrawal of natalizumab ? Neurology 75 2010 831 833
17. O. Stüve, P.D. Cravens, E.M. Frohmans, J.T. Phillips, G.M. Remington, and G. von Geldern Immunologic, clinical and radiological status 14 months after cessation of natalizumab therapy Neurology 72 2009 396 401
18. M. Kaufman, R. Lee, and H. Norton Course of relapsing-remitting multiple sclerosis before, during and after natalizumab Mult Scler December 6 2010 10.1177/1352458510389103 Online First